Yue Hsin Lin
Gründer bei LIN BIOSCIENCE, INC.
Vermögen: 77 Mio $ am 30.04.2024
Aktive Positionen von Yue Hsin Lin
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
LIN BIOSCIENCE, INC. | Gründer | 12.05.2016 | - |
Vorsitzender | 12.05.2016 | - | |
Investor Relations Kontakt | 12.05.2016 | - | |
Vorstandsvorsitzender | 01.06.2016 | 01.04.2022 | |
BELITE BIO, INC | Vorstandsvorsitzender | 27.03.2018 | - |
Vorsitzender | 27.03.2018 | - | |
Gründer | 27.03.2018 | - | |
Belite Bio LLC
Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The private company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | Präsident | 01.10.2021 | - |
RBP4 Pty Ltd. | Direktor/Vorstandsmitglied | 01.08.2018 | - |
Vorstandsvorsitzender | 01.04.2021 | - | |
Belite Bio Holdings Corp. | Vorstandsvorsitzender | 01.12.2017 | - |
Vorsitzender | 01.06.2016 | - | |
Präsident | 01.10.2021 | - | |
Belite Bio (HK) Ltd. | Direktor/Vorstandsmitglied | 01.06.2021 | - |
Karriereverlauf von Yue Hsin Lin
Ehemalige bekannte Positionen von Yue Hsin Lin
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CVie Therapeutics Ltd.
CVie Therapeutics Ltd. BiotechnologyHealth Technology Founded in 2013, CVie Therapeutics Ltd. is a subsidiary of Windtree Therapeutics, Inc. The private company is based in Taipei, Taiwan. The Taiwanese company develops and researches drugs. | Geschäftsführer | 01.01.2014 | 01.01.2016 |
Präsident | 01.01.2014 | 01.01.2016 | |
OBI PHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2010 | 01.01.2014 |
ASLAN PHARMACEUTICALS LIMITED | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2014 | - |
Ausbildung von Yue Hsin Lin
The Trustees of Columbia University in The City of New York | Masters Business Admin |
University of Pennsylvania | Undergraduate Degree |
University of Hong Kong | Masters Business Admin |
The University of Sydney | Doctorate Degree |
London Business School | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 5 |
Taiwan | 4 |
Hong Kong | 3 |
Operativ
Chief Executive Officer | 4 |
Chairman | 3 |
Masters Business Admin | 3 |
Sektoral
Consumer Services | 6 |
Health Technology | 6 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
OBI PHARMA, INC. | Health Technology |
ASLAN PHARMACEUTICALS LIMITED | Health Technology |
LIN BIOSCIENCE, INC. | Health Technology |
Private Unternehmen | 6 |
---|---|
CVie Therapeutics Ltd.
CVie Therapeutics Ltd. BiotechnologyHealth Technology Founded in 2013, CVie Therapeutics Ltd. is a subsidiary of Windtree Therapeutics, Inc. The private company is based in Taipei, Taiwan. The Taiwanese company develops and researches drugs. | Health Technology |
Belite Bio LLC
Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The private company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | Health Technology |
Belite Bio, Inc. | |
RBP4 Pty Ltd. | |
Belite Bio Holdings Corp. | |
Belite Bio (HK) Ltd. |
- Börse
- Insiders
- Yue Hsin Lin
- Erfahrung